NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 420
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has received three new patent awards. According to the announcement, the company was awarded two new patents in its epilepsy patent family; both awards were granted in the United States. The U.S. patents, which cover both swallowed capsules and dissolvable oral tablets, complement research indicating DehydraTECH-CBD has potential to decrease epileptic seizures in rodents and to be absorbed into the bloodstream more effectively than the current treatments. In addition, Lexaria was awarded a patent in Japan in is antiviral agent patent family. The new patents bring the total of Lexaria patents to 41 worldwide.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer